• Norsk
  • English

Aktuelt

Press release - Novozymes

Novozymes Biopharma collaborates with the University of Oslo to develop enhanced albumin fusion technology that tailors the half-life of proteins

Albufuse® Flex next-generation technology has been developed to tailor and control the pharmacokinetics of target proteins and peptides for flexible, optimal use.

INVEN2-PRISEN

Har du en idé til nytt produkt eller tjeneste?

Send inn din idé og vinn 100.000 kroner til utvikling av idéen.

Pages